Home » News: Ben Venue to Exit Contract Manufacturing Business
News: Ben Venue to Exit Contract Manufacturing Business
A Boehringer Ingelheim GmbH plant that has caused shortages in drug supplies will exit the pharmaceutical contract-manufacturing business, as it faces a Canadian ban on the importation of some of its drugs.
Boehringer's Ben Venue Laboratories unit, which manufactures injectable and inhaled drugs for major companies including Pfizer Inc. and Johnson & Johnson, will exit the contract-manufacturing business in a transition over the next several years, spokesman Jason Kurtz said Friday.
Ben Venue is making the move to simplify its business model and focus on its Bedford Laboratories generics business. The move could compound recent drug shortages affecting numerous manufacturers, which have forced some U.S. hospitals to ration or restrict use of certain drugs, and sent patients on a hunt for pharmacies with drugs in stock. Ben Venue, which operates a plant in suburban Cleveland, will work with its customers to minimize supply disruptions. Other divisions of Germany's Boehringer Ingelheim will continue to perform contract-manufacturing services, Kurtz said.
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »